| Name | Title | Contact Details |
|---|
SCA`s vision is to be the partner of choice for physicians, hospitals, and health systems in developing and operating ambulatory surgery centers and surgical hospitals across the country and in enhancing hospital-based surgical departments. SCA owns and/or provides management services to 210 ambulatory surgery centers, surgical hospitals, and hospital surgery departments, in partnership with approximately 7,500 physicians and in affiliation with 110 health systems. SCA`s clinical systems, service line growth strategies, benchmarking processes, and efficiency programs create measurable advantage for surgical facilities – clinically, operationally, and financially.
Helix Medical is a Carpinteria, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mahoning County is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and advocacy, and our Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. Our Curaleaf network of operating companies collectively employs a national workforce of over 500 people. Plans for additional growth are actively in place.
Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications.